**Core tip:** Gastric cancer is the fifth most frequently diagnosed cancer and the second leading cause of cancer-related death globally. Despite a decrease in the overall incidence of gastric cancer in recent decades, the incidence of the subgroup of patients with signet-ring cell carcinoma is growing. This study provides evidence that neoadjuvant chemotherapy does not provide any survival advantage in gastric signet-ring cell carcinoma. For resectable gastric signet-ring cell carcinoma, surgery should be the primary therapy.

INTRODUCTION
============

Gastric cancer is the fifth most frequently diagnosed cancer and the third leading cause of cancer-related deaths worldwide\[[@B1]\]. Despite a decrease in the overall incidence of gastric cancer in recent decades, the incidence of the patient subgroup with signet-ring cell carcinoma (SRCC) is growing\[[@B2],[@B3]\]. According to the World Health Organization classification, SRCC is a histological type where more than 50% of the tumor contains extracellular mucinous pools. Studies have suggested that the biological behavior of SRCC is essentially different from that of other cancers with other cell types\[[@B4],[@B5]\]. SRCC is associated with a worse prognosis in advanced stages\[[@B6]-[@B8]\]. Therefore, a multimodal treatment strategy, including neoadjuvant chemotherapy (NAC), needs to be developed and established to improve patient outcomes. Theoretically, the administration of chemotherapy before surgical resection can address micrometastatic lesions and down-stage the disease.

Some studies have investigated the benefit of NAC in gastric SRCC. However, the results are inconsistent. Earlier research showed that NAC was associated with better outcomes, though the response to NAC was relatively weak in gastric SRCC\[[@B9]\]. Conversely, other studies suggested that NAC provided no survival benefit in patients with gastric SRCC\[[@B10],[@B11]\]. Moreover, some studies found that NAC is an independent predictor of poor survival because of its toxicity\[[@B12]\]. Therefore, we conducted a single-center, large-scale retrospective study to determine if there are benefits of NAC for treating gastric SRCC.

MATERIALS AND METHODS
=====================

Patients and stage
------------------

A total of 144 patients \[staged using the clinical Tumor, Node, and Metastasis (cTNM) staging system\] with cT3/4 stage SRCC (cN any) were identified from a database containing all gastric cancer diagnosed at the National Cancer Center of China between January 2010 and December 2017. Of the 144 SRCC patients, 36 had undergone NAC (NAC group), and 108 were surgery-first (surgery-first group). The decision for NAC had been discussed in a multidisciplinary treatment board and was made at the treating physician's discretion.

Pre-therapeutic staging was performed for all patients using intravenous contrast-enhanced computed tomography (CT), which was repeated after the end of NAC. This study was approved by the institutional review board, which waived the requirement for informed consent due to the retrospective nature of this research.

Neoadjuvant chemotherapy and evaluation of clinical response and toxicity
-------------------------------------------------------------------------

The median number of NAC courses was four (2.25-4.75), and eleven (30.6%), nine (25.0%), seven (19.4%), four (11.1%), and five (13.9%) for the treated patients who received the SOX, DOS, Xelox, Folfox6, and DOX regimens, respectively. Toxicity and adverse events of NAC were evaluated according to the World Health Organization (WHO) standard criteria. Response to chemotherapy was evaluated by gastroscopy or radiographic examination of the stomach or a CT scan. Post-treatment evaluation of the target lesions was divided into four categories: Complete remission, partial remission, stable disease, and progressive disease according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1).

Surgery and postoperative outcome
---------------------------------

Patients in the NAC group underwent radical gastrectomy after the completion of NAC (3-4 wk). All patients underwent gastrectomy with standard D2 lym-phadenectomy. Specific surgical gastrectomy procedures, including subtotal and total gastrectomy, were selected depending on the location of the primary tumor. The resection margins were intraoperatively examined in frozen sections. Reconstruction of the gastrointestinal passage was performed according to the type of gastrectomy. Intra- and post-operative complications and corresponding outcomes were documented.

Histopathology
--------------

The WHO definition of SRCC was based on a resected specimen or the initial biopsy in cases where there was a complete histopathological response. The WHO defined SRCC by the content of signet ring cell-type cells greater than 50% (Figure [1](#F1){ref-type="fig"}). Histological staging of all tumors was based on the 8th edition of the International Union Against Cancer TNM classification system. The tumor size and presence of lymphovascular or neural invasion were evaluated. A tumor regression grade from 1 to 5 was used as described by Mandard et al\[[@B13]\]. R0 resection was defined as radical resection with tumor-free margins, while R1 and R2 resections were defined as resections with microscopically positive and macroscopically positive resection margins, respectively. Patients who were found to have metastatic disease at the time of surgery but underwent resection were graded with R2 resection.

![Gastric signet-ring cell carcinoma characterized by the presence of classical signet-ring cells (A, H&E, 20×; B, H&E, 40×).](WJG-26-818-g001){#F1}

Follow-up
---------

Overall survival (OS) was calculated from the start of any treatment occurring since diagnosis to the point of death (for any reason), or the most recent follow-up. Data on surviving patients without relapses were censored at the last follow-up.

Statistical analysis
--------------------

Categorical variables were compared using the *χ*^2^ test or Fisher's exact test, while continuous variables were compared using Student's *t*-test or the Mann-Whitney *U* test. We analyzed and compared the NAC and surgery-first groups before and after 1:1 matching on the basis of estimated propensity scores for each patient. The propensity scores were calculated using a logistic regression model to balance the following covariates: Age, sex, comorbidities, tumor location, American Society of Anesthesiology score, and cN stage. Kaplan-Meier survival analysis was conducted for determination of OS and generation of survival curves. Differences in survival curves were analyzed using the log rank test. A Cox proportional hazard model was used to adjust for confounding factors affecting OS. A *P* value \< 0.05 was considered statistically significant. All data analyses were performed using SPSS (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 22.0. Armonk, NY: IBM Corp).

RESULTS
=======

Patients' characteristics
-------------------------

Table [1](#T1){ref-type="table"} shows the clinicopathological characteristics of patients in the NAC and surgery-first groups. Age and tumor location significantly differed between the two groups. On the basis of 1:1 propensity score matching (PSM), 72 patients (36 in the NAC group and 36 in the surgery-first group) were selected for analysis. After PSM, age, sex, body mass index, American Society of Anesthesiologists score, tumor location, cT stage, cN stage, cTNM stage, and comorbidities showed no significant differences between the two groups.

###### 

Demographic and clinical characteristics of patients, *n* (%)

  **Variable**               **All patients**   ***P* value**   **Matched patients**   ***P* value**                 
  -------------------------- ------------------ --------------- ---------------------- --------------- ------------- -------
  Age, yr (mean ± SD)        52 ± 11            57 ± 12         \< 0.05                51.6 ± 11.4     49.9 ± 12.2   0.531
  Sex                                                           0.307                                                1
  Male                       21 (58.3)          75 (69.4)                              21 (58.3)       21 (58.3)     
  Female                     15 (41.7)          33 (30.6)                              15 (41.7)       15 (41.7)     
  BMI, kg/m^2^ (mean ± SD)   24.1 ± 50          23.7 ± 3.4      0.527                  24.1 ± 5.0      23.6 ± 3.4    0.649
  ASA                                                           0.731                                                1
  I-II                       34 (94.4)          99 (91.7)                              34 (94.4)       33 (91.7)     
  III-IV                     2 (5.6)            9 (8.3)                                2 (5.6)         3 (8.3)       
  Comorbidity                                                   0.152                                                1
  Absent                     28 (77.8)          68 (63.0)                              28 (77.8)       27 (75.0)     
  Present                    8 (22.2)           40 (37.0)                              8 (22.2)        9 (25.0)      
  Tumor location                                                0.069                                                0.896
  Upper                      4 (11.1)           32 (29.6)                              4 (11.1)        5 (13.9)      
  Middle                     13 (36.1)          36 (33.3)                              13 (36.1)       14 (38.9)     
  Lower                      19 (52.8)          40 (37.0)                              19 (52.8)       17 (47.2)     
  Clinical T stage                                              1                                                    0.462
  3                          15 (41.7)          46 (42.6)                              15 (41.7)       11 (30.6)     
  4                          21 (58.3)          62 (57.4)                              21 (58.3)       25 (69.4)     
  Clinical N stage                                              \< 0.05                                              0.514
  0                          4 (11.1)           35 (32.4)                              4 (11.1)        7 (19.4)      
  1-3                        32 (88.9)          73 (67.6)                              32 (88.9)       29 (80.6)     
  Clinical TNM stage                                            0.181                                                0.829
  IIB                        4 (11.1)           27 (25.0)                              4 (11.1)        6 (16.7)      
  III                        29 (80.6)          70 (64.8)                              29 (80.6)       28 (77.8)     
  IVA                        3 (8.3)            11 (10.2)                              3 (8.3)         2 (5.6)       

NAC: Neoadjuvant chemotherapy; BMI: Body mass index; ASA: American Society of Anesthesiologists.

Response and toxicity analysis for neoadjuvant chemotherapy
-----------------------------------------------------------

In this study, 18 (50.0%) patients exhibited partial remission while 18 (50.0%) exhibited stable disease; no patient exhibited progressive disease according to contrast-enhanced CT before and after NAC. After surgery, pathologic tumor regression grades of 1 (*n* = 3), 2 (*n* = 4), 3 (*n* = 4), 4 (*n* = 3), and 5 (*n* = 22) were observed (Table [2](#T2){ref-type="table"}). Eight (22.2%) of the thirty-six treated patients experienced at least grade 3-4 toxicity during NAC treatment (Table [3](#T3){ref-type="table"}). The most common grade 3-4 toxicities were leukopenia/neutropenia (16.7%), nausea and vomiting (8.3%), and thrombocytopenia (2.8%).

###### 

Neoadjuvant therapy and response, *n* (%)

  **Neoadjuvant therapy**   ***n* = 36**
  ------------------------- --------------
  Clinical response         
  PR                        18 (50)
  SD                        18 (50)
  Mandard grade             
  1                         3 (8.3)
  2                         4 (11.1)
  3                         4 (11.1)
  4                         3 (8.3)
  5                         22 (61.1)

PR: Partial remission; SD: Stable disease.

###### 

Toxicity occurring during neoadjuvant chemotherapy, *n* (%)

  **Adverse event**         **Total**   **Grade 3/4**
  ------------------------- ----------- ---------------
  Leukopenia/neutropenia    9 (25.0)    6 (16.7)
  Nausea/vomiting           6 (16.7)    3 (8.3)
  Thrombocytopenia          2 (5.6)     1 (2.8)
  Diarrhea                  2 (5.6)     0
  Hand-foot skin reaction   1 (2.8)     0
  Allergy                   1 (2.8)     0
  Alopecia                  1 (2.8)     0
  Liver dysfunction         3 (8.3)     0

Operative characteristics and postoperative course
--------------------------------------------------

The incidences of postoperative complications in the NAC and surgery-first groups were 8.3% and 13% (*P* = 0.563), respectively. After PSM, these incidences were 8.3% and 16.7% (*P* = 0.478), respectively. R0 resection was performed for 88.9% patients in the NAC group and 88.9% for patients in the surgery-first group (*P* = 1.000). After PSM, the rate of R0 resection was comparable between the two groups. Type of surgery, operation time, blood loss, and blood transfusion were similar between the two groups before and after PSM. The ratio of patients who received postoperative adjuvant chemotherapy was similar between the groups before and after PSM (Table [4](#T4){ref-type="table"}).

###### 

Comparison of operative and postoperative parameters between neoadjuvant chemotherapy and surgery-first groups, *n* (%)

  **Variable**                        **All patients**   ***P* value**   **Matched patients**   ***P* value**                 
  ----------------------------------- ------------------ --------------- ---------------------- --------------- ------------- -------
  Type of surgery                                                        0.109                                                0.430
  Total gastrectomy                   24 (66.7)          87 (80.6)                              24 (66.7)       28 (77.8)     
  Subtotal gastrectomy                12 (33.3)          21 (19.4)                              12 (33.3)       8 (22.2)      
  Combined resection                                                     1.000                                                1.000
  Yes                                 1 (2.8)            4 (3.7)                                1 (2.8)         2 (5.6)       
  No                                  35 (97.2)          104 (96.3)                             35 (97.2)       34 (94.4)     
  Resection                                                              1.000                                                1.000
  R0                                  32 (88.9)          96 (88.9)                              32 (88.9)       31 (86.1)     
  R1/R2                               4 (11.1)           12 (11.1)                              4 (11.1)        5 (13.9)      
  Operation time (min)                196 ± 54           197 ± 56        0.961                  196 ± 54        190 ± 49      0.600
  Blood loss (mL)                     144 ± 139          127 ± 140       0.527                  144 ± 139       129 ± 122     0.628
  Blood transfusion                                                      0.495                                                1.000
  Yes                                 32 (88.9)          100 (92.6)                             4 (11.1)        4 (11.1)      
  No                                  4 (11.1)           8 (7.4)                                32 (88.9)       32 (88.9)     
  Morbidity                                                              0.563                                                0.478
  Yes                                 3 (8.3)            14 (13.0)                              3 (8.3)         6 (16.7)      
  No                                  33 (91.7)          94 (87.0)                              33 (91.7)       30 (83.3)     
  Postoperative hospital stay (d)     13.3 ± 4.9         13.9 ± 13.2     0.821                  13.3 ± 4.9      14.2 ± 14.0   0.743
  Borrmann type                                                          0.082                                                0.450
  I                                   3 (8.3)            10 (9.3)                               3 (8.3)         1 (2.8)       
  II                                  10 (27.8)          11 (10.2)                              10 (27.8)       6 (16.7)      
  III                                 17 (47.2)          69 (63.9)                              17 (47.2)       22 (61.1)     
  IV                                  6 (16.7)           18 (16.7)                              6 (16.7)        7 (19.4)      
  Tumor size (cm)                     5.9 ± 3.3          5.9 ± 2.9       0.995                  5.9 ± 3.2       6.0 ± 3.5     0.927
  Neural invasion                                                        0.700                                                0.474
  Yes                                 18 (50.0)          74 (68.5)                              17 (47.2)       13 (36.1)     
  No                                  18 (50.0)          34 (31.5)                              19 (52.8)       23 (63.9)     
  Lymphovascular invasion                                                0.848                                                0.341
  Yes                                 17 (47.2)          55 (50.9)                              18 (50.0)       23 (63.9)     
  No                                  19 (52.8)          53 (49.1)                              18 (50.0)       13 (36.1)     
  Pathological tumor classification                                      0.001                                                0.039
  (y)pT0-1                            5 (13.9)           0 (0)                                  5 (13.9)        0 (0)         
  (y)pT2                              0 (0)              1 (0.9)                                0 (0)           1 (2.8)       
  (y)pT3                              9 (25.0)           40 (37.0)                              9 (25.0)        15 (41.7)     
  (y)pT4a/4b                          22 (61.1)          67 (62.0)                              22 (61.1)       20 (55.6)     
  Pathologic nodal classification                                        0.09                                                 0.671
  (y)pN0                              12 (34.3)          15 (13.9)                              12 (34.3)       8 (22.2)      
  (y)pN1                              3 (8.6)            12 (11.1)                              3 (8.6)         3 (8.3)       
  (y)pN2                              7 (20.0)           28 (25.9)                              7 (20.0)        7 (19.4)      
  (y)pN3                              13 (37.1)          53 (49.1)                              13 (37.1)       18 (50.0)     
  Adjuvant chemotherapy                                                  1.000                                                0.396
  Yes                                 26 (72.2)          77 (71.3)                              26 (72.2)       30 (83.3)     
  No                                  10 (27.8)          31 (28.7)                              10 (27.8)       6 (16.7)      

NAC: Neoadjuvant chemotherapy.

Pathological findings
---------------------

Following PSM, (y)pT categories after NAC were significantly less advanced than those after initial gastrectomy in the overall cohort; this finding was not observed for the (y)pN stage (Table [4](#T4){ref-type="table"}).

Long-term outcomes
------------------

The median follow-up was 46.4 mo and comparable between the NAC and surgery-first groups. The 5-year OS rates in the NAC and surgery-first groups were 50.0% and 65.0% (*P* = 0.235), respectively, before PSM and 50% and 64.7% (*P* = 0.192), respectively, after PSM (Figure [2](#F2){ref-type="fig"}). Univariate and multivariate analyses conducted before PSM revealed that lymphovascular invasion \[hazard ratio (HR) = 2.210; 95%CI: 1.168-4.184; *P* = 0.015) and tumor size (≥ 5 cm; HR = 2.154; 95%CI: 1.129-4.109; *P* = 0.020) were associated with OS. Multivariate analysis after PSM revealed that tumor size (≥ 5 cm) was a significant predictor of OS (HR = 3.804; 95%CI: 1.471-10.027; *P* = 0.006). However, NAC was not an independent prognostic factor both before and after PSM (Table [5](#T5){ref-type="table"}).

![Comparison of overall survival. A: Comparison of overall survival between neoadjuvant chemotherapy and surgery-first before propensity score matching; B: Cumulative survival rates between neoadjuvant chemotherapy and surgery-first after propensity score matching. There was no statistically significant difference between the two groups. NAC: Neoadjuvant chemotherapy.](WJG-26-818-g002){#F2}

###### 

Univariate analysis of overall survival before and after propensity score matching

  **Variable**                                 **All patients (*n* = 144)**   **Matched patients (*n* = 72)**                          
  -------------------------------------------- ------------------------------ --------------------------------- ---------------------- -----------
  Age: \< 60 yr *vs* ≥ 60 yr                   1.248 (0.669-2.330)            0.486                             0.778 (0.308-1.965)    0.595
  Sex: Male *vs* female                        0.991 (0.525-1.869)            0.977                             0.974 (0.432-2.194)    0.949
  Comorbidity: Present *vs* absent             1.228 (0.664-2.271)            0.513                             1.830 (0.782-4.281)    0.163
  NAC: Yes *vs* No                             1.466 (0.777-2.768)            0.235                             1.709 (0.756-3.816)    0.192
  Extent of gastrectomy: Subtotal *vs* total   1.394 (0.966-1.883)            0.079                             1.282 (0.479-3.435)    0.621
  Tumor location: Lower *vs* upper             1.128 (0.507-2.514)            0.767                             0.676 (0.218-2.522)    0.676
  Tumor location: Middle *vs* upper            1.750 (0.758-3.832)            0.197                             0.758 (0.228-2.522)    0.651
  Tumor size: \> 5 cm *vs* ≤ 5 cm              2.429 (1.282-4.603)            **0.006**                         4.765 (1.886-12.038)   **0.001**
  cT stage: T4a/4b *vs* T3                     0.834 (0.461-1.570)            0.548                             1.347 (0.575-3.153)    0.492
  cN stage: N1-3 *vs* N0                       1.748 (0.839-3.641)            0.136                             0.971 (0.332-2.844)    0.957
  Lymphovascular invasion: Yes *vs* No         2.291 (1.233-4.256)            **0.009**                         2.600 (1.141-5.928)    **0.023**
  Neural invasion: Yes *vs* No                 1.390 (0.736-2.652)            0.310                             2.304 (0.953-5.567)    0.064
  Adjuvant chemotherapy: Yes *vs* No           0.673 (0.357-1.270)            0.222                             0.654 (0.271-1.581)    0.346

NAC: Neoadjuvant chemotherapy.

DISCUSSION
==========

The incidence of gastric SRCC is increasing, especially among young patients. It is still unclear whether NAC contributes to improved survival of patients with gastric SRCC. To our knowledge, there have been only three reports on this subject, and the results of those studies are inconsistent\[[@B9]-[@B11]\]. Our study revealed that the 5-year cumulative survival rates were comparable between the NAC and surgery-first groups before and after PSM, with the findings suggesting that upfront surgery may be a reasonable treatment option for patients with locally advanced gastric SRCC.

The FRench Eso-GAstric Tumors working group published the results of a retrospective national French survey study, including 924 locally advanced gastric SRCC patients from 1997 to 2010. In this cohort, 18.5% of the patients received NAC. The study found that NAC provided no survival benefit in patients with gastric SRCC and similar rates of R0 tumor resection between the NAC and surgery-first groups. Moreover, no significant differences were observed in (y)pT category, (y)pN category, mean number of dissected lymph nodes, mean number of invaded lymph nodes, and pathological Tumor-Node-Metastasis (pTNM) stage\[[@B10]\]. In other words, NAC did not result in any tumor downsizing. However, Heger et al\[[@B9]\] reported that NAC was associated with significantly increased rates of complete resection (76.0% in the NAC group *vs* 60.7% in the surgery-first group; *P* = 0.010), improved (y)pT category, improved (y)pN category, and significantly less explorations or palliative resections, and was an independent predictor of improved survival for patients with gastric SRCC\[[@B9]\]. In our study, we detected significantly less advanced (y)pT for patients after NAC despite comparable pretreatment stages between the two groups after PSM. However, NAC did not improve the R0 resection rate or result in lymph node downstaging. Furthermore, the 5-year cumulative survival rates were comparable between the NAC and surgery-first groups both before and after PSM. Ronellenfitsch et al\[[@B14]\] conducted a meta-analysis to identify predictors of postoperative survival following NAC for gastric cancer and found the (y)pT stage lost significance as an independent predictor of postoperative survival, while only (y)pN stage and resection status after NAC remained independent prognostic predictors. In our study, we observed downstaging of the T stage, but not the N stage, which may explain why there was no survival benefit from NAC for gastric SRCC.

Many studies have demonstrated that SRCC had different infiltrative and metastatic mechanisms, and SRCC is relatively insensitive to chemotherapy\[[@B15]\]. Roncati et al\[[@B16]\] also demonstrated that SRCC has a great capacity of diffusion through the gastric wall and extended neo-lymph angiogenesis and is not accompanied by an effective immunological response. However, there is no real understanding of the chemoresistance mechanisms of SRCC. It is reported that SRCC lacks free ribosomes but is rich in lysosomes and mucus, which impedes anticancer drugs\[[@B17]\]. Therefore, there is a pressing need to explore SRCC biology to understand the chemoresistance mechanisms involved. Although there is no standardized NAC, regimens based on oxaliplatin, docetaxel, or 5-fluorouracil and their modifications are the most common options for gastric cancer. In our study, SOX, Xelox, DOX, and DOS regimens were used. Additionally, it is reported that toxicity is associated with higher rates of non-R0 resection, increased postoperative mortality, and reduced long-term survival\[[@B12]\]. In our study, toxicity remained acceptable, and NAC did not increase postoperative mortality.

The classification of gastric cancer is complicated due to the coexistence of different histological features in the same tumor\[[@B18]\]. Lauren's classification and the WHO system are the most widely used. The WHO defined true SRCC by the content of signet ring cell-type cells greater than 50%. The concordance of the pre-therapeutic biopsy and the final histopathological results in SRCC after resection should be considered. The high agreement is reported with an accuracy of 92.5% in a retrospective analysis with particular emphasis on SRCC\[[@B19]\], whereas the experienced group from Cologne reported an agreement in 74% of biopsies and resected specimens in untreated patients\[[@B18]\]. As initial diagnostic biopsies prove to be reliable in making an SRCC diagnosis, they may also be relied upon to define the therapeutic strategy.

Nevertheless, there are several limitations to the current study. First, as a retrospective analysis, this study is subject to possible selection bias, even though we used PSM to reduce bias, which was intended to mimic randomized controlled trials. Second, regimens and the indications for NAC were not standardized; therefore, the effects of different NAC regimens were not analyzed. Third, the median follow-up period was as short as 46.4 mo. Thus, there is a possibility that, in some cases, death could still have occurred and missed during the short follow-up period.

This study suggests that NAC does not provide a survival advantage for gastric SRCC, and upfront surgery should be the primary therapy for resectable gastric SRCC. Future studies that better stratify the SRCC components are warranted.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Some studies have investigated the benefit of neoadjuvant chemotherapy (NAC) in gastric signet-ring cell carcinoma (SRCC). However, the results are inconsistent. Earlier research showed that NAC was associated with better outcomes, though the response to NAC was relatively weak in gastric SRCC. The benefit of NAC for patients with SRCC of the stomach is controversial.

Research motivation
-------------------

Earlier research showed that NAC was associated with better outcomes, though the response to NAC was relatively weak in gastric SRCC. Conversely, other studies suggested that NAC provided no survival benefit in patients with gastric SRCC. Moreover, some studies found that NAC is an independent predictor of poor survival because of its toxicity. We conducted a single-center, large-scale retrospective study to determine if there are benefits of NAC for treating gastric SRCC.

Research objectives
-------------------

This study aimed to evaluate the perioperative and long-term outcomes of NAC for locally advanced gastric SRCC.

Research methods
----------------

This study identified patients with locally advanced SRCCs of the stomach diagnosed by using the clinical Tumor-Node-Metastasis staging system. The histologic and prognostic effects of NAC were assessed. The overall survival rates were used as the outcome measure to compare the efficacy of NAC *vs* surgery-first treatment in the selected patients.

Research results
----------------

The R0 resection rates were 88.9% and 86.1% in the surgery-first and NAC groups after propensity score matching (PSM), respectively. The median follow-up period was 46.4 mo. The 5-year overall survival rates of the NAC group and surgery-first group were 50.0% and 65.0%, before PSM and 50% and 64.7% after PSM.

Research conclusions
--------------------

NAC provides no survival benefit in patients with locally advanced gastric SRCC. And, for resectable gastric SRCC, upfront surgery should be the primary therapy.

Research perspectives
---------------------

Future studies that better stratify the SRCC components are warranted.
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